Sherene Loi, MBBS, PhD, FRACP, FAHMS, Peter MacCallum Cancer Centre at the University of Melbourne, Melbourne, Australia, discusses current attitudes towards immunotherapy use in early-stage triple negative breast cancer (TNBC). Clinical trial evidence has shown improved pathologic complete response (pCR) rates attributable to neoadjuvant immunotherapy in TNBC. However, current data only reflects short-term outcomes, and how these findings will translate to long-term survival benefits is unclear. Prof. Loi also discusses preclinical investigations into the best biological setting for immunotherapy, sharing data from mouse models that support the use of a neoadjuvant approach. This interview took place during the 17th St. Gallen International Breast Cancer Conference.
Research funding to institution: Novartis, Bristol Meyers Squibb, Merck, Puma Biotechnology, Eli Lilly, Nektar Therapeutics Astra Zeneca, Roche-Genentech, Seattle Genetics. Consultancy (not compensated): Seattle Genetics, Novartis, Bristol Meyers Squibb, Merck, AstraZeneca, Roche-Genentech. Consultancy (paid to institution): Aduro Biotech, Novartis, GlaxoSmithKline, Roche-Genentech, Astra Zeneca, Silverback Therapeutics, G1 Therapeutics, PUMA Biotechnologies, Seattle Genetics, Bristol Meyers Squibb. Scientific Advisory Board Member: Akamara Therapeutics. Supported by the National Breast Cancer Foundation of Australia Endowed Chair and the Breast Cancer Research Foundation, New York.